Signal Pharma Tariffs 2026: Supply Chain & Manufacturing Impacts

Summary

President Trump signed a Section 232 proclamation on 2 April 2026 imposing tariffs of up to 100% on patented pharmaceuticals, active pharmaceutical ingredients and key starting materials, based on a Commerce Department finding that about 53% of patented pharmaceutical products distributed domestically are produced abroad and only 15% of patented APIs by volume are made domestically. The tariff structure is staged: a 100% default rate, a reduced 20% rate for companies with approved onshoring plans, and a temporary 0% rate through 2029 for firms pairing onshoring with most-favoured-nation pricing agreements. New duties take effect 31 July 2026 for 17 large named companies — including Eli Lilly, Merck, Johnson & Johnson and Pfizer — though most have secured exemptions via administration agreements, and 29 September 2026 for all other companies; the EU, Japan, Korea, Switzerland and Liechtenstein face a 15% rate and the UK 10%. Since Eli Lilly's initial $27 billion commitment, 13 more manufacturers have pledged a combined total exceeding $480 billion in US-based production over four to ten years, pointing to 22 new manufacturing sites and roughly 44,000 new jobs; more than 80% of supply chain leaders reported direct impact from the tariffs. Pfizer separately secured a three-year exemption through MFN pricing and production commitments.